European Pharmaceutical Review
JULY 13, 2023
3 With established drug development pathways, we are accustomed to a rigid structure of translation from bench to bedside. While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful.
European Pharmaceutical Review
DECEMBER 16, 2022
According to a report by Future Market Insights (FMI), the global Alzheimer’s therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 9.3 FMI stated drug manufacturers have been unable to validate the significant clinical benefits of treatment for numerous new compounds due to strict regulations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 24, 2022
GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds.
Pharmaceutical Technology
DECEMBER 5, 2022
Despite this, the medical use of cannabinoid drugs is heavily restricted, including being banned in 137 countries, according to the United Nations. Cannabinoid-based drugs are derived from compounds found in the cannabis plant. Cannabinoid receptors fall into two categories: CB1 and CB2 receptors.
Express Pharma
APRIL 4, 2024
Advantages of lipids and essential factors in selection Lipid-based formulations play a pivotal role in drug discovery and delivery, enhancing bioavailability by controlling therapeutic compounds’ solubility, permeability, absorption, distribution, and metabolism.
pharmaphorum
FEBRUARY 19, 2021
Rigel’s clinical-stage R552 is the main asset in the deal – which also includes $835 million in development, regulatory, and commercial milestones – but Lilly has also taken rights to preclinical-stage follow-ups that can cross into the brain and may have potential in central nervous system disorders.
European Pharmaceutical Review
MARCH 4, 2024
Indeed, in 2022, biologics constituted 40 percent of all US Food and Drug Administration (FDA) approved drugs, projecting a compound annual growth rate (CAGR) of 9.5 Anna has a medical degree and a postgraduate degree in healthcare management and is an expert in all stages of drug development. percent through 2027.
Expert insights. Personalized for you.
88 
Let's personalize your content